Commentary & Perspectives

What Dentistry Must Learn About Compounded Drugs

From GLP-1 medications to gum therapy, the surge in compounded drugs raises critical issues for patient safety and professional responsibility.

Share

The rise of compounded semaglutide, an active ingredient in weight-loss and diabetes medications, underscores the safety and ethical concerns related to compounded drugs. Compounded minocycline gels are being marketed as alternatives to FDA-approved Arestin for periodontitis treatment, raising issues around safety, efficacy, and regulation. Unlike standardized FDA products, compounded medications lack rigorous testing, increasing the risk of complications. Dentists must evaluate their prescribing practices and prioritize informed consent to ensure patient safety.

Original Source(s)

What Dentistry Must Learn About Compounded Drugs

  • by Richard H. Nagelberg

  • March 1, 2026

Related Content

Childhood Oral Health Linked to Adult Cardiovascular Risk

Study links childhood dental disease with higher incidence of ischemic heart disease, myocardial infarction, and ischemic stroke in adulthood.

Simplifying Adhesive Dentistry Without Compromise

All-Bond Universal from BISCO offers flexibility across etch modes, materials, and clinical applications.

  • March 1, 2026

  • 7 min
Q&A: Clinical Strategies Shaping Predictable Adhesive Outcomes

A discussion with Matthew R. Miller, DDS

  • March 1, 2026

  • 8 min